28 results about "Mouse Hippocampus" patented technology

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The application discloses an application of Campanula medium in treatment of perimenopausal depression, and a method is as follows: Campanula medium is added into 10 times of distilled water in weight, decocted for 1 h and filtered, residues are added with 8 times of distilled water, and then decocted for 1 h and filtered, and filtrates are combined, and concentrated into 1 g / mL of medicinal liquid according to medicinal material, so that Campanula medium medicinal liquid is obtained. According to the experimental result, Campanula medium can improve the depression and anxiety behavior of PMD model mice. Campanula medium can improve the hippocampus tissue morphology and structure of the PMD model mice, increase the neuron Nissl body abundance of the hippocampus, promote the ER-BDNF-TrkB path, improve the monoamine neurotransmitter level, correct the HPA axis hyperactivity, and thus improve the depression behavior.

The invention relates to the technical field of learning and memory ability evaluation, and provides a mouse hippocampus learning and memory ability comprehensive evaluation method and system based on a Morris water maze, the method is different from a traditional method for evaluating learning and memory only through an incubation period, a mouse behavior character stability and swimming skill dual evaluation mechanism is innovatively introduced, and the method is suitable for comprehensive evaluation of learning and memory ability of a mouse hippocampus. And in combination with a training adaptation period, behavior path analysis and weighted scoring of multi-dimensional behavior indexes, precise quantification of the hippocampus dependency space learning and memory ability is realized. The experimental indexes comprise swimming speed, path length, target quadrant residence time and incubation period, and performing standardized calculation after weight assignment to generate a memory ability evaluation score. According to the invention, the scientificity, stability and experimental repeatability of an evaluation result are improved, and the method is suitable for mouse cognitive function evaluation under various research situations such as drug intervention, neurodegenerative disease models and the like.

This invention provides the application of *Ackermania guangxiensis* extracellular polysaccharide in the preparation of anti-aging products, belonging to the technical field of microbial polysaccharide pharmaceutical applications. This invention extracts extracellular polysaccharides from *Ackermania guangxiensis* using the TCA precipitation method. Animal experiments show that *Ackermania guangxiensis* extracellular polysaccharide can effectively reduce MDA content in aging model mice while increasing SOD activity; it improves the thinning of the dermal layer, reduction and loosening of collagen fibers, and other signs of aging in model mice, and increases the hydroxyproline content in the skin; furthermore, it can activate the expression of BDNF and TrKB genes in the mouse hippocampus and alleviate problems such as slow movement, cognitive impairment, and memory decline in model mice. Therefore, the *Ackermania guangxiensis* extracellular polysaccharide provided by this invention has good anti-aging and antioxidant activity and can be used to prepare various anti-aging products.

The application discloses application of TESC as an Alzheimer's disease prevention and treatment target and relates to the field of biological medicines. A TESC overexpression (TESC-OE) hippocampal neuron cell line is constructed through lentivirus transfection, and the result shows that TESC-OE has the ability to resist A beta-induced neuron apoptosis and synapse damage. A TESC overexpression model in the hippocampus of a mouse is constructed through stereotactic injection of an adeno-associated virus, and the result shows that the hippocampal gray matter volume in the brain of the TESC-OE mouse is significantly larger than that of a wild type mouse. A beta stereotactic modeling is performed on the basis of TESC overexpression in the hippocampus, and the result shows that the TESC-OE mouse can significantly resist A beta-induced hippocampal atrophy, learning and memory dysfunction and impaired synaptic plasticity. Immunoblotting analysis reveals the molecular mechanism that TESC can increase the expression of anti-apoptotic genes in the hippocampus and reduce the expression of pro-apoptotic genes to exert a neuroprotective effect.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD73 positive NK cells of umbilical cord blood from different starting sources and application of the CD73 positive NK cells to treatment of Alzheimer's disease. The CD73 + NK cells differentiated from different initial cell types (CD34 positive cells, CD3 negative / CD56 positive cells and CD56 negative cells) of umbilical cord blood are studied, it is found that all the initial cell types of umbilical cord blood sources can be differentiated into the CD73 + NK cells, 34 +-73-NK cells show a higher growth rate, 56-73-NK cells show higher cytotoxicity, and the CD73 + NK cells can be differentiated into the CD73 + NK cells. And the overall effect of the 56-73-NK cell is superior to that of the 34 < + >-73-NK cell. Further research shows that the CD73 + NK can inhibit activation of STZ injection mouse hippocampal microglia and astroglia, so that the neuroinflammation of the hippocampal is reduced, and a new solution is expected to be provided for treatment of AD.

The invention discloses a pharmaceutical composition for promoting neuron neogenesis and a method for promoting neuron neogenesis by using a gastrodia elata extract or an adenosine analogue. The gastrodia elata extract comprises gastrodin, gastrodigenin, a parishins compound, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde (4-hydroxybenzaldehyde). The invention also discloses a method for promoting neuron neogenesis by using the gastrodia elata extract or the adenosine analogue. The gastrodia elata extract provided by the invention has aging-retarding activity on nerve cells and can induce mouse hippocampal neuronal neogenesis.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The present application mainly relates to the separation and identification and application of active ingredients in traditional Chinese medicine, and specifically discloses a separation and purification of a steroidal saponin compound in Allii Macrostemonis Bulbus. According to the physical and chemical properties and high-resolution electrospray mass spectrometry (HR-ESI-MS), one-dimensional / two-dimensional nuclear magnetic resonance spectroscopy (1D- / 2D-NMR) and other spectral technologies, the structure of the compound is identified, the structure is analyzed and the molecular formula is determined, and finally named as Allii Macrostemonis Bulbus saponin U. The pharmacological activity of Allii Macrostemonis Bulbus saponin U is studied through in vitro cell experiments, and it is found that Allii Macrostemonis Bulbus saponin U significantly improves the cell viability of mouse hippocampal neurons after glutamate treatment, has good neuroprotective activity, and can be used for the preparation and application of anti-nerve injury drugs.

The invention relates to the technical field of bioactive peptides, in particular to application of sipunculus nudus polypeptide in preparation of a neuroprotective drug. According to the specific technical scheme, firstly, sipunculus nudus oligopeptide is obtained through enzymolysis and an ultrafiltration membrane separation technology, the sipunculus nudus oligopeptide is separated and purified through sephadex chromatography, and on the basis of a high-glucose-induced mouse hippocampal neuron HT22 cell damage model, the collected components are separated and purified to obtain the sipunculus nudus oligopeptide. The neuroprotective effects of the sipunculus nudus oligopeptide and the separated components thereof are deeply discussed, and then the components in the sipunculus nudus oligopeptide are further separated and purified and subjected to mass spectrum peptide sequence identification by adopting reverse-phase high performance liquid chromatography. Experimental results show that the three components separated from the sipunculus nudus oligopeptide through sephadex chromatography can effectively improve the cell activity of HT22 cells after high glucose damage, and accumulation of ROS (reactive oxygen species) in the cells and occurrence of apoptosis are remarkably reduced.

The invention relates to casein peptide hydrolysate and application thereof in preparation of drugs for preventing or treating nerve aging, and belongs to the technical field of biological medicines. The casein hydrolysate is obtained by fermenting a casein solution with the probiotic bifidobacterium longum BNCC 185354, and the obtained casein hydrolysate has superoxide anion free radical scavenging capacity, can prolong the telomere length of the hippocampus of a subacute aging model mouse and relieve DNA oxidative damage of the hippocampus of the mouse. The brand-new casein peptide with both brain-accessible activity and biological activity is further screened from casein hydrolysate, free radicals can be removed, nerve cell inflammation can be eliminated, and therefore nerve aging is delayed. The casein peptide and the casein hydrolysate provided by the invention can be applied to preparation of drugs for preventing and / or treating nerve aging, and have good application prospects.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The application discloses a target strategy and a drug intervention method for improving Primrose syndrome, and belongs to the technical field of biological medicine. The experiment proves that Momordin Ic can significantly improve the SUMO level of ZBTB20 in vitro cells or Primrose syndrome (PS) mice, can effectively improve the defects of reduced neuron dendritic branching in the hippocampal CA1 region of the PS mice in pathology, can enhance the complexity, and can improve the cognitive and emotional disorders such as memory impairment and anxiety-like behavior of the PS mice to different degrees in behavior. The application discloses that Momordin Ic can improve the PS-related neuropathological changes and behavioral cognitive defects by targeting the SENP1-ZBTB20-SUMO pathway, and provides a new candidate molecule and a clear action target for developing potential therapeutic drugs for Primrose syndrome.

The invention relates to the technical field of biology, and particularly discloses a polypeptide composition as well as a preparation method and application thereof. The polypeptide composition comprises American ginseng peptide, rhizoma polygonati peptide and ginkgo fruit peptide. The mass ratio of the American ginseng peptide to the rhizoma polygonati peptide to the ginkgo nut peptide is (20-100): (5-15): (20-150). According to the polypeptide composition disclosed by the invention, the specific raw materials are matched, so that the sleep latency period of an insomnia mouse is effectively shortened, the sleep maintenance time of the mouse is prolonged, the content of 5-HT in hippocampal tissues of the mouse is increased, and the effect of improving sleep is achieved. The raw materials used in the polypeptide composition are safe, and the polypeptide composition can effectively assist sleep and improve insomnia for a long time and has a good application prospect.

The invention discloses an application of polypeptide in preparation of antidepressant drugs, and belongs to the field of biological medicine, the polypeptide is neuropeptide PEN or a functional fragment and a derivative thereof, and the PEN is one of a plurality of derivative peptides formed by cutting a protein precursor proSAAS existing in a central nervous system of a mammal through proprotein convertase. Research finds that PEN as an endogenous polypeptide can significantly shorten the immobility time of a mouse in a tail suspension experiment and a forced swimming experiment and improve the depression-like behavior of the mouse, shows an obvious anti-depression effect, and has no obvious influence on the movement function of the mouse. A further research result shows that the anti-depression mechanism of PEN is related to inhibition of NMDAR2B / CaMKII signals of a mouse hippocampus and increase of ERK1 / 2 protein activity of the hippocampus. The invention discovers potential application of PEN in preparation of antidepressant drugs for the first time, and provides a new target and theoretical basis for development of novel, safe and effective antidepressant drugs.

The application discloses application of methyl palmitate in preparation of a medicine for treating and / or preventing senility and related cognitive impairment, and belongs to the technical field of biological medicine. The application proves by a cell experiment that methyl palmitate can significantly inhibit D-galactose-induced SH-SY5Y cell senility, and effectively reduce the expression level of senility-related proteins P53 and P16. The application proves by a behavior experiment that methyl palmitate can significantly improve the cognitive index of a senility model mouse, shorten an escape latency, and effectively improve learning ability reduction, spatial memory decline and cognitive function impairment caused by senility. In addition, methyl palmitate can significantly enhance the long-term potentiation effect of the hippocampal CA1 region of the senility model mouse, and reverse senility-related synaptic transmission damage. The application discloses the application of methyl palmitate in resisting neural senility and improving senility-related cognitive impairment, and provides a new candidate molecule for preparing a medicine for treating neurodegenerative diseases.

This invention discloses a 3-hydroxypyridinone derivative, its preparation method, and its applications. This 3-hydroxypyridinone derivative, through structural modification of the 3-hydroxypyridinone core, significantly enhances its anti-ferroptosis activity against hippocampal neurons in HT-22 mice. In vitro experiments show that its inhibitory effect on ferroptosis is more than twice that of the positive control deferoxone. Furthermore, the 3-hydroxypyridinone derivative can also chelate Fe... 3+ To alleviate iron-mediated Aβ 1‑42 Protein aggregation and its cytotoxicity. This invention also provides synthetic routes, purification methods, and in vitro activity evaluation systems for 3-hydroxypyridinone derivatives, offering structural optimization strategies and candidate compounds for the development of drugs targeting iron metabolism disorders.

The application provides a circular RNA circ_0004801 and application thereof in Alzheimer's disease treatment; a nucleotide sequence of the circular RNA circ_0004801 is shown as SEQ ID NO:1. Expression of the circular RNA circ_0004801 in hippocampus tissue of AD mice is significantly up-regulated, the circular RNA circ_0004801 acts as a "sponge" of miR-7688-5p, and plays a role by regulating TTBK1 expression and tau phosphorylation level. Knocking down the circular RNA circ_0004801 can obviously improve spatial learning and memory of 3xTg mice, significantly reduce tau protein phosphorylation level in hippocampus and NFTs density in hippocampus DG region. Therefore, the circular RNA circ_0004801 and miR-7688-5p can be used as a new target for treating AD. The application first finds that the circular RNA circ_0004801 regulates TTBK1 through a ceRNA mechanism, thereby driving tau hyperphosphorylation, and provides a new molecular target for early intervention treatment of AD based on circRNA and miRNA.

This invention belongs to the field of medical technology, specifically relating to the preparation of CD73-positive NK cells from umbilical cord blood of different origins and their application in the treatment of Alzheimer's disease. This invention studies CD73-positive NK cells differentiated from different cell types originating from umbilical cord blood (CD34-positive cells, CD3-negative / CD56-positive cells, and CD56-negative cells). + NK cells were found to differentiate into CD73 from all initial cell types derived from umbilical cord blood. + NK cells, and 34 + -73-NK cells showed a higher growth rate, 56 － -73-NK cells exhibited stronger cytotoxicity, and 56 － -73-NK cells showed better overall efficacy than 34- + -73-NK cells. Further research indicates that CD73 + NK cells can inhibit the activation of microglia and astrocytes in the hippocampus of STZ-injected mice, thereby reducing neuroinflammation in the hippocampus and potentially providing a new solution for the treatment of AD.

The invention discloses a biomarker for treating post-stroke depression and application thereof, and belongs to the technical field of biomedicine. The biomarker is a micro ribonucleic acid-146 (miR-146) family member, and specifically comprises miR146b (micro ribonucleic acid)-3p, miR146a (micro ribonucleic acid)-5p, miR146a (micro ribonucleic acid)-3p and miR146b (micro ribonucleic acid)-5p. Experiments prove that the expression of miR146b-3p and miR146a-5p in hippocampal tissues of mice in a PSD state is up-regulated, the expression of miR146a-3p and miR146b-5p is down-regulated, and the expression of the subtypes can be regulated to a normal level by using radix bupleuri liver soothing powder (CSS). The biomarker can be used for PSD diagnosis, illness state evaluation and treatment effect monitoring, provides a target spot for screening and research and development of PSD treatment drugs, and has important clinical application value and scientific research significance.

The present invention relates to a composition and a method of utilizing Gastrodia elata extract or an adenosine analog to promote neurogenesis, wherein the G. elata extract includes gastrodin, gastrodigenin, parishins, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde. The G. elata extract of the present invention exhibits anti-aging activity on nerve cells and can induce neurogenesis in mouse hippocampus.

The invention belongs to the technical field of organic probe molecule analysis and detection, and discloses a light-operated electrochemical molecular probe (TPMP), a preparation method thereof and application of the light-operated electrochemical molecular probe in detection of copper ions (Cu < 2 + >). The molecular structural formula of the probe is as follows: hydroquinone and 2-nitrobenzyl bromide react to prepare a compound 1, and then the compound 1 and pyridine formyl chloride hydrochloride are subjected to esterification reaction under the catalysis of triethylamine to obtain a target product. The probe realizes light-operated open-type electrochemical detection of Cu < 2 + > based on a sequential response mechanism activated by Cu < 2 + > specific recognized-365 nm ultraviolet light, has no electrochemical signal in darkness, quantitatively releases electroactive substances after light activation and generates significant response, has a detection limit as low as 30 nM, has ultrahigh selectivity on Cu < 2 + >, and can effectively resist biological matrix interference. The fluorescent probe is applied to quantitative detection of free Cu < 2 + > in a hippocampal dialysate of an AD (Alzheimer's disease) model mouse.

The invention discloses application of lactobacillus rhamnosus to preparation of a product for treating hippocampus injury caused by chronic fatigue. The invention discloses that the lactobacillus rhamnosus BD4047 has good neuron and synaptic protection capability for the first time, and can improve hippocampus neuron damage caused by chronic fatigue, increase the density of hippocampus neuron dendritic spines, increase the length of the dendritic spines and increase the number of branch intersection points of the dendritic spines; the synaptic injury caused by chronic fatigue is improved, the synaptic gap width is reduced, the thickness of a synaptic compact region is increased, the length of a synaptic active region is prolonged, the increase of the number of synaptic vesicles and the increase of the number of SYP spots are promoted, and a remarkable synaptic repair effect is achieved; in addition, mouse hippocampus microglial cell activation caused by chronic fatigue can be inhibited, hippocampus injury caused by chronic fatigue and diseases related to the hippocampus injury can be comprehensively improved, and therefore the composition has a wide prospect.

The invention relates to a polypeptide, a derivative of the polypeptide, a conjugate of the polypeptide and new application of the polypeptide. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 1. The polypeptide can reverse the weakening of cell proliferation activity of mouse hippocampal neuron cells HT-22 induced by an A beta1-40 oligomer, and reduce p-Tau protein overexpression and cell axon structure damage in the HT-22 cells caused by the A beta1-40 oligomer; the polypeptide promotes the proliferation and differentiation of the neural stem cell line C17.2 cells treated by the A beta1-40 oligomer; the polypeptide can significantly improve Alzheimer's disease related pathological changes in cerebral cortex and hippocampus of a mouse and promote neurogenesis of the hippocampus, so that related cognitive functions of learning, memory and the like of an Alzheimer's disease model mouse are recovered, and the effect of treating the Alzheimer's disease is achieved; the polypeptide can be used for preparing a low-toxicity, safe and effective Alzheimer's disease therapeutic agent, and a new way is provided for treating Alzheimer's disease.

This invention belongs to the field of chemical technology, specifically relating to a method for the artificial synthesis of theanine-fructosyl-glucose (TFG) and its applications. Theanine-fructosyl-glucose (TFG) is a Maillard reaction product with significant antioxidant activity, but it has not yet been systematically studied. This study provides an efficient method for the artificial synthesis of TFG, reducing synthesis costs and providing a material basis for subsequent research. This method is economical, efficient, simple to operate, and safe, making it suitable for industrial production. Subsequently, in vitro activity screening of HT22 mouse hippocampal neurons and HUVEC human vascular endothelial cells confirmed that TFG can significantly alleviate hydrogen peroxide (H2O2)-induced cellular oxidative damage. Based on its synergistic protective effect on neurons and the vascular endothelial system, TFG is suitable for developing antioxidant drugs for the treatment of Alzheimer's disease.

The invention discloses a method for regulating a hippocampus immune balance mechanism of a stress depression mouse through electroshock, and relates to the field of nerves and spirit. Comprising the following steps: constructing a chronic unpredictable mild stress CUMS depression-like mouse model, and performing intervention by adopting electroshock pricking ECS; depression-like behaviors are evaluated through behavioral tests, including a sweet water preference experiment, an open field experiment and a tail suspension experiment; the method comprises the following steps: collecting hippocampus tissues of a mouse, and detecting the level of inflammatory factors and the polarization state of microglial cells by using ELISA, Western blot and an immunofluorescence technology; and evaluating the activation of the microglial cells by combining PET-CT scanning with a [< 18 > F] DPA-714 tracer agent. By integrating clinical, animal and cell experiments, the invention reveals that ECT recovers the balance of microglial cells M1 / M2 through a Chuk / NF-kB signal channel, thereby relieving the depressive symptom.

This invention provides lactylated PRDX5 protein, its products, and applications, belonging to the field of biomedical technology. This invention reveals the crucial role of PRDX5 K71 site lactylation modification in the pathological process of COPD, showing abnormally elevated levels of lactylation in hippocampal neurons of COPD mice, which is closely related to the occurrence and development of cognitive impairment in mice. Simultaneously, it provides a specific intervention protocol targeting this site. Stereoscopic injection of recombinant adeno-associated virus PRDX5 K71R mutant reduces or blocks the likelihood of lactylation modification at the K71 site, effectively improving learning, memory, and spatial orientation abilities in COPD mice. This provides new molecular targets and experimental evidence for the study of the mechanisms of cognitive impairment and targeted prevention and treatment.

The invention discloses a compound with remarkable noradrenaline (NE) reuptake inhibition activity and application of the compound in preparation of an anti-depression drug. The compound is a compound Oreonudine F. The preparation method of the compound comprises the following steps: extracting an overground part of wild poppy by using 95% ethanol, acidifying an extract, extracting by using petroleum ether, adjusting an acid water layer to be alkaline by using alkali liquor, and extracting by using chloroform. The chloroform extraction part is subjected to silica gel column chromatography, C18 ODS column chromatography, preparative high performance liquid chromatography separation and the like, and the compound Oreonudine F is obtained. In-vitro activity test results show that the compound Oreonudine F significantly inhibits reabsorption of NE (the inhibition rate is 45.6%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine F is superior to that of a positive control drug amitriptyline (the inhibition rate is 35.5%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.